Camlin Fine Sciences per share figures

Share price at each year-end
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
₹0.27₹1.46−₹8.03−₹5.58₹3.45
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
₹0.22₹1.42−₹7.94−₹5.50₹3.41
₹54.19₹54.19₹47.98₹51.64₹52.16
₹96.92₹89.71₹88.68₹96.32₹107.04
—₹4.27₹1.42₹8.30₹3.24
₹1.28₹1.28−₹0.84₹4.68−₹5.95
19.219.218.816.715.7
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

CAMLINFINE₹82.32

Camlin Fine Sciences Limited

· Chemicals
₹ CrorePeersCLEANDEEPAKNTRBAYERCROPTIRUMALCHMATULSHKPAUSHAKLTDANURASMcap ₹1,581 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
₹ per share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Basic EPS3.45-5.58-8.031.460.27
Diluted EPS3.41-5.50-7.941.420.22
Book Value per Share52.1651.6447.9854.1954.19
Revenue per Share107.0496.3288.6889.7196.92
Cash Flow per Share3.248.301.424.27—
Free Cash Flow per Share-5.954.68-0.841.281.28
Shares Outstanding (cr)15.716.718.819.219.2
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.